Literature DB >> 3278879

GnRH agonists and antagonists. Current clinical status.

M Filicori1, C Flamigni.   

Abstract

Gonadotrophin-releasing hormone (GnRH) analogues offer a novel approach for the non-steroidal manipulation of the reproductive endocrine axis. GnRH agonists are now effectively employed in the management of precocious puberty, prostate and breast cancer, endometriosis, uterine leiomyoma, polycystic ovarian disease, and various other disorders. Unfortunately, contraceptive applications of GnRH agonists have been disappointing. The availability of slow release depot formulations of GnRH agonists, and the development of GnRH antagonists may further optimise and extend the clinical application of these compounds.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3278879     DOI: 10.2165/00003495-198835010-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  116 in total

1.  Use of intranasal luteinizing hormone-releasing hormone agonist in uterine leiomyomas.

Authors:  R Maheux; A Lemay; P Merat
Journal:  Fertil Steril       Date:  1987-02       Impact factor: 7.329

2.  Treatment of breast cancer with gonadotropin-releasing hormone.

Authors:  A Manni; R Santen; H Harvey; A Lipton; D Max
Journal:  Endocr Rev       Date:  1986-02       Impact factor: 19.871

3.  Combined treatment with ketoconazole and luteinising hormone releasing hormone analogue: a novel approach to resistant progressive prostatic cancer.

Authors:  J M Allen; D J Kerle; H Ware; A Doble; G Williams; S R Bloom
Journal:  Br Med J (Clin Res Ed)       Date:  1983-12-10

4.  Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists.

Authors:  G Tolis; D Ackman; A Stellos; A Mehta; F Labrie; A T Fazekas; A M Comaru-Schally; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

5.  Leuprolide versus diethylstilbestrol for metastatic prostate cancer.

Authors: 
Journal:  N Engl J Med       Date:  1984-11-15       Impact factor: 91.245

6.  Luteolysis induced by a luteinizing hormone-releasing hormone agonist is prevented by human chorionic gonadotropin.

Authors:  C Bergquist; S J Nillius; L Wide
Journal:  Contraception       Date:  1980-10       Impact factor: 3.375

Review 7.  Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty.

Authors:  P A Boepple; M J Mansfield; M E Wierman; C R Rudlin; H H Bode; J F Crigler; J D Crawford; W F Crowley
Journal:  Endocr Rev       Date:  1986-02       Impact factor: 19.871

8.  Therapeutic use of pituitary desensitization with a long-acting lhrh agonist: a potential new treatment for idiopathic precocious puberty.

Authors:  W F Crowley; F Comite; W Vale; J Rivier; D L Loriaux; G B Cutler
Journal:  J Clin Endocrinol Metab       Date:  1981-02       Impact factor: 5.958

9.  Sensitivity of pituitary and corpus luteum responses to single intranasal administration of (D-ser[TBU]6-des-gly-NH2(10)) luteinizing hormone-releasing hormone ethylamide (Buserelin) in normal women.

Authors:  A Lemay; N Faure; F Labrie
Journal:  Fertil Steril       Date:  1982-02       Impact factor: 7.329

10.  Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH.

Authors:  M Filicori; E Campaniello; L Michelacci; A Pareschi; P Ferrari; G Bolelli; C Flamigni
Journal:  J Clin Endocrinol Metab       Date:  1988-02       Impact factor: 5.958

View more
  11 in total

Review 1.  Functional domains of the gonadotropin-releasing hormone receptor.

Authors:  S C Sealfon; R P Millar
Journal:  Cell Mol Neurobiol       Date:  1995-02       Impact factor: 5.046

Review 2.  Endometriosis 1990. Current treatment approaches.

Authors:  R L Barbieri
Journal:  Drugs       Date:  1990-04       Impact factor: 9.546

3.  QSAR models for predicting the activity of non-peptide luteinizing hormone-releasing hormone (LHRH) antagonists derived from erythromycin A using quantum chemical properties.

Authors:  Michael Fernández; Julio Caballero
Journal:  J Mol Model       Date:  2007-01-10       Impact factor: 1.810

Review 4.  Drug treatment in precocious puberty.

Authors:  M D Wheeler; D M Styne
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

Review 5.  Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions.

Authors:  P Chrisp; K L Goa
Journal:  Drugs       Date:  1991-02       Impact factor: 9.546

Review 6.  Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in benign gynaecological disorders.

Authors:  C M Perry; R N Brogden
Journal:  Drugs       Date:  1996-02       Impact factor: 9.546

Review 7.  Nafarelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical potential in sex hormone-related conditions.

Authors:  P Chrisp; K L Goa
Journal:  Drugs       Date:  1990-04       Impact factor: 9.546

Review 8.  Leuprorelin. A review of its pharmacology and therapeutic use in prostatic disorders.

Authors:  P Chrisp; E M Sorkin
Journal:  Drugs Aging       Date:  1991 Nov-Dec       Impact factor: 3.923

9.  Gonadotropin-releasing hormone agonists administration in polycystic ovary syndrome. Effects on bone mass.

Authors:  G Lupoli; C Di Carlo; V Nuzzo; G Vitale; D Russo; S Palomba; C Nappi
Journal:  J Endocrinol Invest       Date:  1997-09       Impact factor: 4.256

Review 10.  Nilutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer.

Authors:  M G Harris; S G Coleman; D Faulds; P Chrisp
Journal:  Drugs Aging       Date:  1993 Jan-Feb       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.